- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02585375
Latanoprost Preserved Versus Unpreserved: Effect on Tear Film Thickness as Measured With OCT
Topical antihypertensive eye drops are a key element of modern antiglaucoma treatment. Most of these eye drops contain preservatives to allow for the use of multi-dose containers. In the recent years evidence has, however, accumulated that these preservatives may induce ocular surface disease (OSD). This is particularly true for the most widely used preservative, benzalkonium chloride (BAK). Whereas this is well documented in many in vitro and animal studies, evidence from clinical trials is sparse. The only randomized masked study that showed superiority is a pivotal company-sponsored study indicating improved tolerability and reduced hyperemia of unpreserved versus preserved latanoprost eye drops.
The investigators have recently introduced an optical coherence tomography (OCT) technology that provides a resolution as high as 1.2 µm for the human cornea. Using this technology the investigators were able to show that tear film thickness (TFT) is negatively correlated with symptoms of OSD. Changes in TFT can be assessed with very high sensitivity below the level of resolution as also evident from studies after administration of lubricants.
In the present study, the investigators hypothesize that switching glaucoma patients from preserved prostaglandin analogues to unpreserved latanoprost is associated with an increase in TFT as measured with OCT. As a control the investigators will use preserved latanoprost and the study hypothesis will be tested in a randomized, controlled, single-masked parallel group design. TFT is chosen as main outcome variable, standard measures for signs and symptoms of OSD are selected as secondary outcomes. The present study may provide valuable information on the superiority of unpreserved versus preserved therapy.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Katarzyna J Witkowska, MD, Phd
- Phone Number: 29810 +43 1 40400
- Email: katarzyna.witkowska@meduniwien.ac.at
Study Locations
-
-
-
Vienna, Austria, 1090
- Recruiting
- Department of Clinical Pharmacology, Medical University of Vienna
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women aged over 18 years
- Diagnosed primary open angle glaucoma treated with preserved prostaglandin analogues containing at least 0.001% BAK for at least 6 months OR
- Patients with ocular hypertension treated with preserved prostaglandin analogues containing at least 0.001% BAK for at least 6 months
- IOP ≤ 21 mmHg in the study eye at the screening examination (under treatment)
- Mean tear film thickness at the screening visit < 4µm in the study eye
Exclusion Criteria:
- Participation in a clinical trial in the 3 weeks before the screening visit
- Severe visual field loss as defined as an MD of -15 or worse in the study eye
- Symptoms of a clinically relevant illness in the 3 weeks before the first study day
- Presence or history of a severe medical condition that will interfere with the study aim as judged by the clinical investigator
- Sjögren's syndrome
- Stevens-Johnson syndrome
- Presence or history of a severe ocular condition that will interfere with the study aim as judged by the clinical investigator
- Presence or history of allergic conjunctivitis
- Treatment with corticosteroids in the 4 weeks preceding the study
- Wearing of contact lenses
- Topical treatment with any ophthalmic drug in the 4 weeks preceding the study except glaucoma medication or topical lubricants
- Ocular infection
- Ocular surgery in the 6 months preceding the study (except laser trabeculoplasty)
- Pregnancy, planned pregnancy or lactating
- Contraindication against the use of topical prostaglandin therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients with glaucoma or ocular hypertension 1
35 patients with glaucoma or ocular hypertension
|
|
Active Comparator: Patients with glaucoma or ocular hypertension 2
35 patients with glaucoma or ocular hypertension
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Tear film thickness measured with high resolution optical coherence tomography (OCT)
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Tear Break Up Time
Time Frame: 6 months
|
6 months
|
Tear Film Osmolarity
Time Frame: 6 months
|
6 months
|
Conjunctival hyperemia score
Time Frame: 6 months
|
6 months
|
Staining of the cornea with fluorescein according to Oxford scale
Time Frame: 6 months
|
6 months
|
Impression cytology according to Haller-Schober scale 2006
Time Frame: 6 months
|
6 months
|
Schirmer 1 test
Time Frame: 6 months
|
6 months
|
Ocular Surface Disease Index score
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OPHT-081214
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ocular Hypertension
-
Western Galilee Hospital-NahariyaUnknown
-
Laboratoires TheaCompletedOcular Hypertension GlaucomaBulgaria
-
Santen Inc.Completed
-
West Virginia UniversityUniversity of PittsburghRecruitingGlaucoma and Ocular HypertensionUnited States, United Kingdom, Canada
-
University Hospital, GenevaTerminatedGlaucoma and Ocular HypertensionSwitzerland
-
Santen Inc.Completed
-
Maastricht University Medical CenterCompletedCorticosteroid Induced Ocular Hypertension/GlaucomaNetherlands
-
Santen Inc.CompletedA Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHTGlaucoma and Ocular HypertensionUnited States
-
Bausch & Lomb IncorporatedCompletedGlaucoma | Open Angle or Ocular HypertensionUnited States
-
Nicox Ophthalmics, Inc.CompletedGlaucoma, Open-Angle | Hypertension, OcularUnited States
Clinical Trials on Preservative-free latanoprost 50µg/ml
-
Association for Innovation and Biomedical Research...European Vision Institute Clinical Research NetworkCompletedOcular Hypertension | GlaucomaUnited Kingdom, Switzerland, Belgium, Italy, Portugal, Austria
-
CHA UniversitySamil Pharmaceutical Co., Ltd.CompletedOcular Hypertension | GlaucomaKorea, Republic of
-
Rigshospitalet, DenmarkLaboratoires TheaRecruitingOcular Hypertension | GlaucomaDenmark
-
Adapt Produtos Oftalmológicos Ltda.WithdrawnOcular Hypertension | Open Angle GlaucomaBrazil
-
Direction Centrale du Service de Santé des ArméesRecruitingAge-Related Macular Degeneration | Dry Eye SyndromesFrance
-
Klinički Bolnički Centar ZagrebUniversity of ZagrebRecruitingOcular Hypertension | Primary Open-angle GlaucomaCroatia
-
AurolabUnknownOcular Hypertension | Glaucoma, Open-AngleIndia
-
Oregon Health and Science UniversityActive, not recruitingCesarean SectionUnited States
-
Adolfo Daniel Rodriguez-CarrizalezHospital Civil de GuadalajaraRecruitingDiabetic Retinopathy | Dry Eye Syndromes | Oxidative Stress | Tear Film DeficiencyMexico
-
Universitaire Ziekenhuizen KU LeuvenAllerganUnknownOcular Hypertension | GlaucomaBelgium, Austria, Italy, Switzerland, United Kingdom